Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (2415)	12/25/1998 3:00:00 PM
From: TomOrt	Read Replies (1) \| Respond to of 4676

From the "Medicine Man" talks.com by George Stasen Christmas Stocking Stuffers: Naming More Names December 28, 1998 -- Continuing on from last week, here are four more biotech stocks that have the potential to develop into first-rate bargains by this time next year. The same caveats prevail. The list is only meant to tweak interest with an all-too-brief description and some feel for the developments that might turn the stock into an outstanding performer. All of the companies merit further research. Lastly, there is no implied attractiveness in the order in which the companies are presented. The companies are: ISIS Pharmaceuticals Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) is the leader in the discovery and development of therapeutic compounds based on antisense technology. These compounds are designed to be much more selective and to interact at a different or earlier stage in the disease process than traditional drugs. Antisense drugs have the potential to address a virtually unlimited range of diseases, and they can be designed with uncharacteristic speed and efficiency. Isis is also recognized as a leader in combinatorial drug discovery. These technologies, antisense and combinatorial drug discovery, enable Isis to find drugs to treat a variety of infectious and inflammatory diseases and cancer. Isis has six compounds in human clinical trials and several additional compounds in preclinical development. The hot button for Isis stock is wider recognition by Street research analysts of the enormous potential in the company's achievement in creating a medical breakthrough with its antisense technology. Just last August, the FDA cleared Isis-developed Vitavene for marketing, the first drug ever to work through an antisense mechanism of action. Furthermore, as an underscore to the company's determination to maintain its leadership position in antisense, a week ago, Isis announced that it had purchased fro m Gilead Sciences (Nasdaq: GILD) the holdings of its antisense patent estate. This acquisition included patents and patent applications covering a broad proprietary suite of antisense chemistry and antisense drug delivery systems. This purchase augments Isis' substantial patent estate which has over 100 issued patents and over 30 U.S. patent applications allowed. The website for more detailed information on Isis is www.isip.com. Since its Aug. '98 plunge, Isis Pharmaceutical stock has recovered about 60% from a low of $7.